You are here: Industry Insights > Gritstone

News List

Gritstone bio and CEPI extend deal to develop Omicron vaccine candidate Pharmaceutical-Technology
December 08, 2021
Gritstone bio and the Coalition for Epidemic Preparedness Innovations (CEPI) have expanded their agreement to develop a self-amplifying mRNA (SAM) vaccine against the Omicron variant of the SARS-CoV-2 virus.
Omicron variant minimally impacts Gritstone’s Covid-19 vaccines Pharmaceutical-Technology
December 01, 2021
Gritstone bio has reported that the mutations seen within the Omicron (B.1.1.529) variant of the SARS-CoV-2 virus does not affect the viruses’ T cell epitopes (TCEs) delivered along with its self-amplifying...
Gilead, Gritstone Enter Vax Platform Pact for HIV Cure contractpharma
February 02, 2021
Aims to develop HIV-specific vaccine using Gritstone’s prime-boost vaccine platform with antigens developed by Gilead.
Gritstone Advances Second Generation COVID-19 Vaccine americanpharmaceuticalreview
January 20, 2021
Gritstone Oncology is advancing development of a second-generation vaccine against SARS-CoV-2, the virus that causes COVID-19, with potential for both prolonged protection and potency against Spike mutants.
Gritstone ramps up bispecifics with new antibody therapeutics chief fiercebiotech
December 28, 2018
Gritstone Oncology has appointed Jonah Rainey, Ph.D., to head up its bispecific antibody program as it moves into lead optimization.....
bluebird bio, Gritstone Enter Collaboration contractpharma
August 28, 2018
bluebird bio, Inc. and Gritstone Oncology, Inc. announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy.
Bluebird, Gritstone inks deal to develop cancer cell therapies biospectrumasia
August 24, 2018
Gritstone Oncology will receive $20M in an upfront payment and an additional $10M in the form of a Series C preferred equity investment.
Bristol-Myers Squibb, Gritstone Oncology Announce Collaboration americanpharmaceuticalreview
July 24, 2018
Bristol-Myers Squibb and Gritstone Oncology announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Gritstone’s personalized neoantigen immunotherapy,
Gritstone, Bristol-Myers Squibb to trial immunotherapy combos in solid tumors fiercebiotech
July 20, 2018
Gritstone Oncology and Bristol-Myers Squibb are partnering to test the former's personalized neoantigen treatment in combination with the latter's Opdivo and Yervoy in patients with advanced solid tumors. They expect to start a phase 1 trial before the en